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To investigate the effects of blood glucose control with antihyperglycemic agents with 
minimal hypoglycemia risk on cardiovascular outcomes in patients with type 2 diabetes 
(T2D). 
Materials and Methods 
Randomized controlled trials (RCTs) comparing the relative efficacy and safety of 
antidiabetic drugs with less hypoglycemia risk were comprehensively searched in 
MEDLINE, Embase, and the Cochrane Library up to January 27, 2018. Mixed-effects 
meta-regression analysis was conducted to explore the relationship between haemoglobin 
A1c (HbA1c) reduction and the risk of major adverse cardiovascular events (MACE), 










myocardial infarction, stroke, cardiovascular death, all-cause death, and hospitalization 
for heart failure. 
Results 
Ten RCTs comprising 92400 participants with T2D were included and provided 
information on 9773 MACE during a median follow-up of 2.6 years. The mean HbA1c 
concentration was 0.42% lower (median, 0.27-0.86%) for participants given 
antihyperglycemic agents than those given placebo. The meta-regression analysis 
demonstrated that HbA1c reduction was significantly associated with a decreased risk of 
MACE (β value, -0.39 to -0.55; P<0.02) even after adjusting for each of the following 
possible confounding factors including age, sex, baseline HbA1c, duration of follow-up, 
difference in achieved systolic blood pressure, difference in achieved body weight, or risk 
difference in hypoglycemia. Lowering HbA1c by 1% conferred a significant risk 
reduction of 30% (95% CI, 17-40%) for MACE. By contrast, the meta-regression 
analysis for trials using conventional agents failed to demonstrate a significant 
relationship between achieved HbA1c difference and MACE risk (P>0.74). 
Conclusions 
Compared with placebo, newer T2D agents with less hypoglycemic hazard significantly 
reduced the risk of MACE. The MACE reduction seems to be associated with HbA1c 
reduction in a linear relationship. 
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Type 2 diabetes (T2D) is associated with an increased risk of cardiovascular (CV) and 
microvascular complications, with a higher risk for all-cause mortality compared with the 
general population 1. More than 29 million people in the United States and 420 million 
globally have T2D, with a projected global prevalence of 642 million by 2040 2,3.  
Conventional T2D drugs in randomized controlled trials, in contrast with the benefits 
on microvascular outcomes, have failed to show consistent beneficial effects on major 
adverse cardiovascular events (MACE) 4-11. Such inconsistent evidence has led to the 
American Heart Association, the American College of Cardiology, and the American 
Diabetes Association providing a conservative class IIb recommendation with level of 
evidence A for the benefit of glycemic control on cardiovascular disease 12. 
Due to concerns regarding increased adverse CV events incurred by new diabetic 
drugs 13, the U.S. Food and Drug Administration and European Medicines Agency 
mandated that new diabetic therapies had to demonstrate CV safety in prospective, 
randomized controlled outcome trials. Although designed to address the safety issue, 
results from recent “cardiovascular outcomes trials” (CVOTs) have confirmed CV safety, 
as well as reduced CV and all-cause mortality in some studies 14-16.  
Recently, we demonstrated that hypoglycemia is associated with an increased risk of 
CV events, all-cause hospitalization, and all-cause mortality in a dose-response manner 
17,18. Another cohort study has also confirmed this positive relationship 19. Given that new 
T2D drugs are less prone to hypoglycemia, their benefit-harm profiles on cardiovascular 
outcomes might be considerably different from that of conventional antihyperglycemic 
agents. Moreover, a previous meta-analysis suggested that there were no significant 










differences in the associations between available classes of glucose-lowering drugs and 
the risk of cardiovascular or all-cause mortalities 20. The meta-regression analysis in this 
study did not evaluate the effect of blood sugar reduction on cardiovascular mortality. We 
therefore hypothesized that the relative risk of MACE associated with the use of new 
T2D drugs is in proportional to the reduction of blood glucose, estimated with 
haemoglobin A1c concentration (HbA1c).  
To test this hypothesis, we conducted a meta-analysis and meta-regression analysis to 
systematically synthesize and investigate the relationship between HbA1c reduction and 
the outcomes of stroke, coronary heart disease (CHD), hospitalization for heart failure 
(HF), cardiovascular death, all-cause mortality and any major adverse cardiovascular 
events in the large endpoint-adjudicated randomized controlled trials for new T2D drugs 
with minimal hypoglycemia risk.  
  










MATERIALS AND METHODS 
The pre-specified protocol for this review was registered with PROSPERO, number 
CRD42017071367, and the study report adhered to the PRISMA statement 21 
recommended by the Enhancing the Quality and Transparency of Health Research 
(EQUATOR) Network (Supplementary Table 1).  
Data Sources and Literature Searches 
We systematically searched MEDLINE, Embase and the Cochrane Library to 
identify all relevant studies from database inception to Jan 27, 2018, using keywords and 
the Medical Subject Headings (MeSH) terms as the following: type 2 diabetes mellitus, 
hypoglycemic agents, diabetes treatment, blood sugar lowering, glucose reduction, 
glycemic control, cardiovascular diseases, myocardial infarction, stroke, and 
cardiovascular mortality (Supplementary Table 2). We limited our search to randomized 
controlled trials, clinical trials or controlled clinical trials. Additional studies were 
retrieved by manually checking the reference lists of reviews, meta-analyses, and original 
publications. No language restrictions were applied on any of these searches. 
Study Selection 
The inclusion criteria for eligible studies required each of the following: (i) 
randomized controlled clinical trials (RCTs) comparing the effects of intensive glucose 
lowering using drugs with a minimal hypoglycemia hazard versus placebo or standard 
care, or comparing one type of antihyperglycemic agent with another type in patients 
with T2D; (ii) reporting major adverse cardiovascular events as the primary outcome and 
adjudicated by an independent committee; (iii) enrolling total number of patients more 
than 1000 22 to avoid the overestimation of the effect sizes from small trials 23; and (iv) 










with a follow-up of more than one year. We excluded trials using mainly insulin, 
sulfonylureas (SUs), or glinides in blood glucose management. The trials investigating 
antidiabetic drugs withdrawn from market were also excluded. 
Two researchers (CJH and WTW) performed the procedure of selecting the studies, 
which were further rechecked by a third researcher (HMC) for accuracy. 
Data Extraction and Quality Assessment 
Relevant data extracted from each eligible trial were collected using a spreadsheet. 
We collected information regarding study and participant characteristics, baseline and 
achieved HbA1c levels, mean difference in HbA1c between intervention and control 
groups, the antidiabetic regimens used, and outcome events. We judged the 
methodological quality of the included trials using the Cochrane Collaboration’s tool for 
assessing the risk of bias 24 and the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) system for rating the quality of evidence 25. Two 
researchers (WTW and CJH) independently performed the data extraction and quality 
appraisal, and any discrepancies were resolved through discussion with a third researcher 
(HMC). 
Outcomes 
Our primary outcome of interest was major adverse cardiovascular events (MACE), 
a composite endpoint consisted of death from cardiovascular causes, nonfatal myocardial 
infarction, or nonfatal stroke. Secondary outcomes were myocardial infarction, stroke, 
death from cardiovascular causes, death from any cause, and hospitalization for heart 
failure according to the definition of each study. Safety outcomes including 
hypoglycemia (any type of event) and severe hypoglycemia (requiring third-party 










assistance) were also evaluated. Although patients on placebo may still receive 
conventional antidiabetic agents, given all other balanced baseline characteristics, the 
relative effects between treatment and control arms on cardiovascular outcomes were 
mainly rendered by the effects of the testing strategies. 
Data Synthesis and Analysis 
In this meta-analysis, we used aggregated data and performed a quantitative 
synthesis of the findings from the included studies. Because all adverse outcomes were 
binary indicators, the relative risk (RR) with 95% confidence interval (CI) was used as 
the measure of the effect of the intervention. For CANVAS program, we calculated a 
time-adjusted risk ratio, given the reported incidence rate (events per 1000 patient-year) 
in each group and the estimated total person-time of the control group, to get an 
approximate estimate of the hazard ratio for every outcome. We obtained the pooled 
estimates of effect measures by using the DerSimonian and Laird random-effects model 
as the primary analysis under consideration of the population variance across studies 26, 
supplement with the analysis of a fixed-effects model. The weighting scheme of the 
Mantel-Haenszel method was applied to both models. Heterogeneity of treatment effects 
among studies was assessed using both Cochran’s Q and Higgins’s I2 statistics 24. 
Publication bias was detected using funnel plots and Egger's regression asymmetry test 27. 
Univariable analysis of mixed-effects meta-regression was performed to explore the 
relationships between the difference in achieved HbA1c and the absolute risk reduction 
(ARR) as well as the relative risk. These relationships were further examined by using 
multivariable meta-regression analysis adjusted for various confounding factors such as 
mean age, proportion of male patients, mean HbA1c at baseline, difference in achieved 










systolic blood pressure (SBP), difference in achieved body weight, median length of 
follow-up, and risk difference in hypoglycemia. Data on mean difference in achieved 
SBP or achieved body weight were not available in SAVOR-TIMI 53 or TECOS trials 
28,29, therefore in meta-regression analysis we replaced the missing data with a value of 
zero according to the findings of neutral effect of SBP or body weight on cardiovascular 
events with DPP4 inhibitor treatment from previous studies 30. To verify our hypothesis, 
we conducted an additional analysis with the data from four large RCTs on 
cardiovascular outcomes, UKPDS 4,5, ADVANCE 7, VADT 9 and ACCORD 31, which 
compared intensive blood glucose reduction versus standard care using conventional 
antihyperglycemic treatment in patients with T2D 32. 
Subgroup analyses by the extents of HbA1c reduction and type of 
antihyperglycemic agents were conducted to evaluate the difference between the 
estimates of treatment effect from subsets of studies. A 2-tailed P value of less than 0.05 
was considered statistically significant. All analyses were performed using R software 
(version 3.1.3, R Foundation for Statistical Computing), Review Manager (version 5.3, 
Cochrane Collaboration), and the Comprehensive Meta-Analysis software package 
(version 2.2.064, Biostat, Englewood, NJ). 
 
  











Of the 4443 articles identified initially, 69 were further reviewed in full-text for 
assessing eligibility. Finally, 10 studies met our inclusion criteria and were chosen for this 
analysis (see Supplementary Figure 1). 
Study Characteristics and Quality Assessment [Table 1] 
All 10 RCTs enrolled a total of 92400 type 2 diabetic patients with established or at 
high risk for cardiovascular disease, with a mean age of 63.5 years, in whom 48106 were 
assigned to receive antihyperglycemic treatment with one of four classes of antidiabetic 
agents (dipeptidyl peptidase 4 inhibitor, glucagon-like peptide 1 receptor agonists, 
sodium-glucose cotransporter inhibitor, and thiazolidinedione) and 44294 to receive 
placebo. These trials followed patients for a median of 1.5 to 3.8 years and recruited more 
than 60% of the men. Most patients had T2D of >10-years duration.  
The included trials had similar baseline HbA1c between treatment and placebo 
groups, and the mean difference in achieved HbA1c varied from 0.27 to 0.86% (mean 
0.42%). All these studies had a low or an unclear risk of bias for 7 domains of potential 
risk of bias (see Supplementary Figure 2 and 3). No clear evidence of publication bias 
was noted for all outcomes by funnel plot and or Egger’s test (all P>0.09) 
(Supplementary Figure 4). 
Achieved HbA1c Difference and Risk of Adverse Events 
Univariable meta-regression analyses showed that the absolute risk reduction for 
MACE (P=0.0005) and stroke (P=0.0044) was proportional to the reduction in achieved 
HbA1c. With an increment of 1% in achieved HbA1c difference, the magnitude of risk 
reduction increased 4.43% for MACE (95% CI, 1.92-6.94%) and 1.92% for stroke (95% 










CI, 0.60-3.23%) (Figure 1A and Supplementary Figure 5). Similarly, a larger reduction in 
achieved HbA1c was significantly associated with a lower relative risk of MACE 
(P=0.0008) and stroke (P=0.0092) (Figure 1B and Supplementary Figure 6). Lowering 
HbA1c by 1% conferred a significant risk reduction of 30% (95% CI, 17-40%) for 
MACE and 40% (95% CI, 15-57%) for stroke. By contrast, using conventional 
antihyperglycemic agents, the results of meta-regression analysis (Figure 1C and D) 
failed to demonstrate a significant relationship between achieved HbA1c difference and 
MACE risk (P>0.74). 
We further performed the multiple meta-regression analyses for MACE and stroke. 
The trend relationships from the estimates of absolute or relative effect of intervention 
were found in MACE after adjusting for each of the following possible confounders 
including age, sex, baseline HbA1c, duration of follow-up, difference in achieved SBP, 
difference in achieved body weight, or risk difference in hypoglycemia (P<0.05 for all 
models) (Table 2 and Supplementary Table 3). 
Effects of Antihyperglycemic Treatment on Major Adverse Cardiovascular Events 
When we evaluated the effectiveness of different extents of lowering HbA1c (Figure 
2), there was significant heterogeneity in the treatment effects across strata (P=0.008; 
I2=79.4%), with greater risk reductions in trials with a ≥0.5% difference in achieved 
HbA1c (relative risk reduction [RRR], 13%; 95% CI, 6-20%; P=0.0008) than in trials 
with a 0.3-0.5% difference (11%; 95% CI, 4%-17%; P=0.002), but no benefits were 
found in trials with a <0.3% difference in achieved HbA1c (0%; 95% CI, -7 to 6%; 
P=0.90). Overall, antihyperglycemic treatment significantly reduced the risk of MACE 
by 8% (95% CI, 3-13%; P=0.002) compared to placebo. 










We also assessed the efficacy of four classes of oral antidiabetic agents in the 
prevention of MACE in patients with T2D. The results showed the effects of 
antihyperglycemic treatment differed between drug classes (P=0.03; I2=65.3%) 
(Supplementary Figure 7). Compared to placebo, GLP-1 receptor agonists (RRR, 9%; 
95% CI, 0-17%; P=0.048), SGLT2 inhibitors (14%; 95% CI, 6-22%; P=0.002), and 
thiazolidinediones (17%; 95% CI, 3-29%; P=0.02) were significantly associated with a 
decreased risk of MACE. A significant treatment effect with DPP4 inhibitors was not 
found.  
Using the GRADE system, the overall quality of the body of evidence was high for 
MACE in comparing antidiabetic drugs to placebo for patients with T2D (Supplementary 
Table 4). Nine fewer MACE (from 3 fewer to 14 fewer) could be prevented per 1000 
patients with T2D receiving antidiabetic drugs compared to placebo. 
Antihyperglycemic Treatment and Hypoglycemia Risk 
The risk of hypoglycemia had no linear relationship with the between-group 
difference in achieved HbA1c (Supplementary Figure 8A), antihyperglycemic treatment 
conferred a significantly higher risk for hypoglycemia than placebo (RR, 1.09; 95% CI, 
1.01-1.18; P=0.03), with the excess risk contributed by DPP4 inhibitors or 
thiazolidinediones use (Supplementary Figure 9). We did not detect an increased risk for 
severe hypoglycemia with antihyperglycemic therapy (Supplementary Figure 8B and 10). 
The quality of evidence was moderate for hypoglycemia and low for severe 
hypoglycemia (Supplementary Table 4), and no publication bias was found (Egger's test 
P=0.1583 for hypoglycemia and 0.6741 for severe hypoglycemia, data not shown). 
DISCUSSION 










The present meta-analysis and meta-regression analysis of the CVOTs (10 trials, 
92400 patients) for antihyperglycemic agents with less hypoglycemia risk, including 
pioglitazone, DPP-4 inhibitors, GLP-1 receptor agonist, and SGLT2 inhibitor, have 
demonstrated clearly that the magnitude of risk reduction of MACE was proportional to 
the differences of HbA1c between treatment and control groups, even after accounting 
for potential confounding factors. The present analysis, without the potential noise of the 
adverse impacts resulting from hypoglycemia 17,18, demonstrates for the first time that 
risk reduction of T2D population in the MACE was proportional to the magnitude of 
HbA1c decrease conferred by antihyperglycemic agents without hypoglycemia hazard. In 
other words, rather than the extra-glycemic actions of individual drugs or classes of drugs, 
the blood glucose reduction may play a more important role than previously expected in 
reducing the risk of MACE by using the antihyperglycemic agents without hypoglycemia 
hazard. 
During about median treatment of 2.6 years, reduction of HbA1c concentration by 1% 
resulted in a significant reduction in the risk of MACE by 30%. This positive correlation 
was consistent with the result of a previous meta-regression analysis 33. Similarly, in 
trials with the use of conventional antihyperglycemic agents, there have been no 
significant association between cardiovascular events and HbA1c reduction. The 
information obtained in our study will be useful for clinicians for selecting the optimal 
antihyperglycemic agents to avoid or reduce the huge health burden resulting from the 
high MACE rate in patients with T2D.  
These results were consistent with our subgroup analysis (Figure 2), whereby the 
higher HbA1c reduction between the treatment and control groups was associated with a 










larger risk reduction in MACE with the same protective result in subgroup analysis by 
different categories of antihyperglycemic agents. With the different benefit-harm profiles 
from the traditional medication, new antihyperglycemic agents, similar to 
antihypertensive 34 and anti-hypercholesterolemia drugs 35, can bring about a predictable 
risk reduction in MACE, which is proportional to the reduction of these risk factors. 
Nevertheless, we cannot exclude the possibility that the benefits observed with GLP-1 
receptor agonists, SGLT2 inhibitors, and thiazolidinediones are at least partly due to 
extra-glycemic actions of these drugs. For example, the SGLT2 inhibitor, empagliflozin, 
markedly and rapidly reduced CV mortality and heart failure hospitalization,14 which may 
be related with hemodynamic or metabolic-associated mechanisms. The GLP-1 receptor 
agonists, liraglutide16 and semaglutide,15 reduced CV death and MACE with beneficial 
effects appearing more slowly, and did not influence heart failure risks, suggesting the 
possible alternative mechanisms of benefit.36 
In currently available trials, the control group is not represented simply by “placebo”: 
study protocols recommend the adjustment of concurrent therapies for reaching an 
optimal glucose control in all patients; as a result, T2D patients in placebo groups are 
more often treated with insulin and SUs than those on active treatment. As shown in a 
previous meta-analysis of 115 randomized trial, the use of the sulfonylurea is associated 
with increased mortality and a higher risk of stroke.37 Moreover, the sulfonylurea did 
increase the risk of hypoglycemic episodes when compared with DPP4 inhibitors 38,39 or 
metformin regardless of the individual sulfonylurea.40 Therefore, it is possible that part of 
the differences in outcome is determined by detrimental effects of conventional therapies 
on some cardiovascular outcomes.  










During the United Kingdom Prospective Diabetes Study,41 risk reductions for 
myocardial infarction and death from any cause emerged in the 10 years follow-up. 
However, the ADVANCE 7 and ACCORD 42 trials suggested that significant differences 
in HbA1c concentration might not confer benefits to macrovascular events and even 
cause an excess risk of all-cause mortality possibly associated with the higher 
drug-related adverse events of the hypoglycemia. A meta-analysis of data from 13 
randomized controlled trials suggested intensive glucose lowering treatment resulted in a 
19% increase in all-cause mortality and a 43% increase in cardiovascular death 43. By 
contrast, one meta-analysis using pooled data from ACCORD, ADVANCE, and UKPDS 
showed an overall reduction in the risk of major cardiovascular events by 9% and a 15% 
reduction in myocardial infarction 6. Another meta-analysis from 5 randomized 
controlled trials of 33040 participants provide reassurance about the effectiveness of 
intensive glycemic control for cardiovascular risk reduction (17% reduction in events of 
non-fatal myocardial infarction and 15% reduction of coronary heart disease) 32.  
Possible explanation of such different results may include that treatment duration was 
shorter than was needed to reveal a clinical benefit 41, thus event rates were lower than 
expected due to improved control of risk factors, differences in glycemic control between 
patients groups were too small to show benefit, and the prevalent side effects of 
hypoglycemia, which may counteract the benefit from intensive glucose control with 
insulin and sulfonylurea 17,18. The last one hypothesis helps explain why the beneficial 
effects of glucose lowering in previous diabetic trials using insulin and sulfonylurea only 
appeared with a longer follow-up duration. It may be because that the risk associated with 
hypoglycemia resulting from conventional antihyperglycemic agents may “dilute” the 










protective effects of blood sugar control. Such “dilution” needs longer follow-up duration 
and a larger event number to counterbalance. Overall, these discrepancies indicate that 
the role of glucose control in patients with T2D who receive glycemic therapy has yet to 
be determined until now.  
Our findings are in agreement with the results of a systematic review which 
investigated the impact of incretin based treatment, including both GLP-1 agonists and 
DPP-4 inhibitors on all-cause mortality in patients with T2D 44. Although no 
meta-regression analysis was conducted in that study, by enrolling few large and several 
small RCTs and registry reports, the results suggested a probable mortality benefit with 
GLP-1 agonists 44.  
In addition to the risk conferred from hyperglycemia, cardiovascular risk may also 
be modulated by various mechanisms; First of all, baseline characteristics, such as 
duration since T2D diagnosis at baseline (≥10 years), the baseline HbA1c concentration, 
and adverse side effects of T2D drugs. In the ACCORD trial, for example, HbA1c fell 
rapidly by around 1.5% within half years and the average HbA1c was less than 6% by 1 
year in intensively treated individuals through aggressive use of bolus insulin dose when 
necessary and receiving greater proportion of rosiglitazone at the end of follow-up 
compared with those receiving standard treatment (92% vs 58%) 42. Adverse effects of a 
2.5 kg difference in weight gain and nearly double severe hypoglycemic episodes 
compared with standard treatment were found. More importantly, our meta-regression 
analysis, accounts for these possible confounding effects and still demonstrated a strong 
significant linear relationship between HbA1c difference and the risk reduction in 
MACE. 










 Despite Dipeptidyl peptidase 4 inhibitor is associated with a low risk of 
hypoglycemia 28, it failed to demonstrate a significant risk reduction in MACE 
(Supplement Figure 7). As suggested by our meta-regression analysis in Figure 1 and 
subgroup analysis by the magnitude of HbA1c reduction in Figure 2, its small benefit on 
MACE in these CV safety trials is probably related to its small magnitude of HbA1c 
differences.  
Antidiabetic drugs with a low hypoglycemic potential can increase the risk of 
hypoglycemia when added to insulin or SUs. If hypoglycemia is detrimental for the 
cardiovascular system, this could reduce an underestimation of the potential benefits of 
the reduction of HbA1c. In order to have a reliable assessment of the effects of the 
improvement of glycemic control on CV events, we would need a large trial on 
intensification of therapy in which insulin and SUs are not allowed or allowed only as 
rescue therapy.  
Study Limitations 
Our study has several potential limitations. First, similar to other meta-analyses, the 
absence of primary data to analyze the effects of intensive glycemic control within 
various patient subgroups by gender, prevalence of cardiovascular disease at baseline, 
comorbidity, duration of T2D, and the selective reporting of primary studies might 
confound our study results. Second, these results should be interpreted carefully because 
of the significant heterogeneity with respect to the demographic characteristics of 
participants, duration of follow-up, and medication for intensive glucose control. Third, 
we cannot provide evidence of superiority or harm of a specific glucose-lowering 
regimen without access to individual participant data. Finally, despite the comprehensive 










literature search, we may have failed to locate some eligible published or unpublished 
studies even we tried to keep the probability of bias to a minimum by developing a 
detailed protocol and using explicit criteria for study selection, data collection, and data 
analysis. Similar to trends reported in previous meta-analysis,6 we believe that we have 
been robust in out methodology and that the results and conclusions would not likely be 
altered substantially and provide reliable recommendation for clinical practice. 
Conclusions 
Compared with placebo, newer T2D agents with less hypoglycemic hazard 
significantly reduced the risk of MACE. The MACE reduction seems to be associated 
with HbA1c reduction in a linear relationship. 
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Figure 1. Univariable meta-regression for the relationship of achieved HbA1c difference 
between intervention and control groups with absolute risk reduction (A) (C) and the 
natural logarithm of a relative risk (B) (D) for MACE in patients with type 2 diabetes, 
according to the trials using antidiabetic agents with minimal hypoglycemia risk or 
conventional drugs as the option of intensive glycemic management. The regression fit 
(solid line) and 95% confidence interval (dash line) are shown. The size of the circle 
represents the weight of each trial and is inversely proportional to the standard error of 
the effect estimate. Beta coefficient depicts a change in absolute or relative effect of 
antihyperglycemic treatment for each 1% difference in achieved HbA1c between 
intervention and control groups. HbA1c = haemoglobin A1c; MACE = major adverse 
cardiovascular event. 


















































































































Placebo 2.875* 61.7 66.1 8† MI, 46.7; CVA, 18.8; 
HTN, 75.4 
7.85† 7/7.6‡ 0.60** 0.4** 4 kg 
raises** 




Placebo 1.5 61† 67.9 7.2† MI, 88.0; HF, 27.9; CVA, 
7.2; HTN, 83.1; CKD, 
29.1 
8.03 7.7/8.06§ 0.36 0.8‡‡ 0.06 kg 
raises 




Placebo 2.1 65.1 66.9 10.3† MI, 37.8; HF, 12.8; HTN, 
81.8; CKD, 15.6 
8 7.6/7.87ǁ 0.27** NR 0.53** 





Placebo 2.08 60.3 69.3 9.3 MI, 22.1; HF, 22.4; CVA, 
5.5; HTN, 76.4; CKD, 
23.2 
7.7 7.32/7.53ǁ 0.27 0.8 0.7 
EMPA-REG 
OUTCOME 14 




Placebo 3.1 63.1 71.5 ≤1 y: 2.6; 
>1-5 y: 15.4; 
>5-10 y: 24.9;
>10 y: 57.1 
MI, 46.6; HF, 10.1; CVA, 
23.3; CKD, 25.9 
8.07 7.55/8ǁ 0.45** 3.43** 1.79** 




Placebo 3 65.5 70.7 11.6 MI, 42.6; HF, 18.0; CVA, 
24.5; CKD, 9.3 
7.2 7.09/7.37ǁ 0.29 NR NR 





Placebo 3.8 64.3 64.3 12.9 MI, 30.7; HF, 17.8; CVA, 
16.1; CKD, 24.7 
8.7 7.54/7.93¶ 0.40 1.2 2.3 





Placebo 2.1 64.6 60.7 13.9 MI, 32.5; HF, 23.6; CVA, 
14.9; HTN, 92.8; CKD, 
28.5 
8.7 7.45/8.3# 0.86†† 1.93†† 3.61†† 
CANVAS program 
48 




Placebo 2.42* 63.3 64.2 13.5 CAD, 56.4; HF, 14.4; 
CVA, 19.3; HTN, 90.0 
8.2 7.73/8.17ǁ 0.58 3.93 1.6 





Placebo 3.2 62† 62 12† CAD, 52.8; HF, 16.2; 
CVA, 17.0; CKD, 21.7 
8.1 7.55/8.01ǁ 0.53 1.57 1.27 
CAD = coronary artery disease; CANVAS = Canagliflozin Cardiovascular Assessment Study; CKD = chronic kidney disease; CVA = cerebrovascular accident; DPP4 = dipeptidyl peptidase 4; ELIXA = 









eEvaluation of Lixisenatide in Acute Coronary Syndrome; EMPA-REG OUTCOME = Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients; EXAMINE = Examination of 
Cardiovascular Outcomes with Alogliptin versus Standard of Care; EXSCEL = Exenatide Study of Cardiovascular Event Lowering; GLP-1 = glucagon-like peptide 1; HbA1c = haemoglobin A1c; HF = heart 
failure; HTN = hypertension; LEADER = Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; MI = myocardial infarction; NR = not reported; PROactive = PROspective 
pioglitAzone Clinical Trial In macroVascular Events; SAVOR-TIMI 53 = Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)–Thrombolysis in Myocardial 
Infarction (TIMI) 53; SBP = systolic blood pressure; SGLT2 = sodium-glucose cotransporter 2; SUSTAIN 6 = Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects 
with Type 2 Diabetes; TECOS = Trial Evaluating Cardiovascular Outcomes with Sitagliptin; TZD = thiazolidinedione 
*Mean value 
†Median value 
‡Calculated by median change from baseline to final visit  
§Calculated by mean change from baseline to the end of the study period 
ǁAverage of mean HbA1c across all visits  
¶Estimated from the HbA1c level at 36 months  
#Estimated from the HbA1c level at week 104 in the group receiving doses of 0.5 mg and 1.0 mg.  
**Difference of estimated achieved HbA1c/SBP/body-weight between intervention and control groups 
††Meta-analysis of mean HbA1c/SBP/body-weight reduction at week 104 in the semaglutide group receiving 0.5 mg and 1.0 mg 
‡‡Estimated from the data reported in 2016 50. 
  











Table 2. Meta-regression analysis for the relationship between achieved HbA1c difference and MACE risk 
 ARR (%) LnRR 
 β P value β P value 
Univariable 4.428 (1.920 to 6.935) 0.0005 -0.474 (-0.751 to -0.197) 0.0008 
Model 1: adjusted for age 4.495 (1.825 to 7.165) 0.0010 -0.502 (-0.790 to -0.214) 0.0006 
Model 2: adjusted for sex 4.945 (1.484 to 8.407) 0.0051 -0.550 (-0.923 to -0.178) 0.0038 
Model 3: adjusted for baseline HbA1c 3.559 (0.576 to 6.542) 0.0194 -0.391 (-0.706 to -0.076) 0.0150 
Model 4: adjusted for follow-up duration 4.212 (1.669 to 6.755) 0.0012 -0.458 (-0.740 to -0.175) 0.0015 
Model 5: adjusted for achieved SBP difference 3.766 (0.467 to 7.066) 0.0253 -0.417 (-0.766 to -0.068) 0.0191 
Model 6: adjusted for achieved body-weight difference 4.410 (1.811 to 7.009) 0.0009 -0.469 (-0.748 to -0.190) 0.0010 
Model 7: adjusted for risk difference in hypoglycemia 4.494 (1.947 to 7.040) 0.0005 -0.487 (-0.772 to -0.201) 0.0008 
Model 8: adjusted for risk difference in severe 
hypoglycemia* 
5.104 (1.349 to 8.859) 0.0077 -0.477 (-0.839 to -0.116) 0.0097 
ARR = absolute risk reduction; HbA1c = haemoglobin A1c; LnRR = natural logarithm of relative risk; MACE = major adverse cardiovascular event; SBP = 
systolic blood pressure 
*The Model was performed on the data from 8 trials with reports of severe hypoglycemia. 
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